2016
DOI: 10.2217/imt-2016-0023
|View full text |Cite
|
Sign up to set email alerts
|

Crisaborole and its Potential Role in Treating Atopic Dermatitis: Overview of Early Clinical Studies

Abstract: Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of patients presenting with mild to moderate disease. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical anti-inflammatory PDE4 inhibitor … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
32
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 58 publications
(32 citation statements)
references
References 80 publications
0
32
0
Order By: Relevance
“…Crisaborole 2% topical ointment, the most recent addition to topical agents for treating mild to moderate AD, provides an improved risk-benefit profile that might be appropriate for some patients. [66][67][68][69][70] The following comments reflect the most recent data and the authors' combined clinical experience with these agents.…”
Section: Commentarymentioning
confidence: 99%
See 4 more Smart Citations
“…Crisaborole 2% topical ointment, the most recent addition to topical agents for treating mild to moderate AD, provides an improved risk-benefit profile that might be appropriate for some patients. [66][67][68][69][70] The following comments reflect the most recent data and the authors' combined clinical experience with these agents.…”
Section: Commentarymentioning
confidence: 99%
“…67 Chemically, crisaborole is a unique boron-based compound-a benzoxaborole-and the configuration of boron within the compound enables synthesis of a low-molecular-weight molecule (251 Da) that facilitates the effective penetration of crisaborole through human skin so that it can target PDE4. 67,70 Systemic exposure varies according to the cutaneous surface treated. Crisaborole is rapidly and substantially metabolized to inactive metabolites, limiting continued exposure and systemic PDE4 inhibition.…”
Section: Topical Calcineurin Inhibitorsmentioning
confidence: 99%
See 3 more Smart Citations